These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 26893063)

  • 1. Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents.
    Maly J; Blachly JS
    Curr Hematol Malig Rep; 2016 Feb; 11(1):52-60. PubMed ID: 26893063
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Therapy in Chronic Lymphocytic Leukemia (CLL).
    Pettijohn EM; Ma S
    Curr Hematol Malig Rep; 2017 Feb; 12(1):20-28. PubMed ID: 28155013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.
    Wiestner A
    Haematologica; 2015 Dec; 100(12):1495-507. PubMed ID: 26628631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies.
    Robak T; Robak P
    Int Rev Immunol; 2013 Aug; 32(4):358-76. PubMed ID: 23617253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia.
    Robak P; Robak T
    Curr Med Chem; 2012; 19(31):5294-318. PubMed ID: 22830347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Towards targeted therapy of chronic lymphocytic leukemia.
    Niemann CU; Jones J; Wiestner A
    Adv Exp Med Biol; 2013; 792():259-91. PubMed ID: 24014301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities.
    Hill RJ; Lou Y; Tan SL
    Int Rev Immunol; 2013 Aug; 32(4):377-96. PubMed ID: 23886341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of chronic lymphocytic leukemia (CLL) in the era of B-cell receptor signal transduction inhibitors.
    Mato A; Jauhari S; Schuster SJ
    Am J Hematol; 2015 Jul; 90(7):657-64. PubMed ID: 25808792
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the B cell receptor pathway in chronic lymphocytic leukemia.
    Davids MS; Brown JR
    Leuk Lymphoma; 2012 Dec; 53(12):2362-70. PubMed ID: 22616724
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bruton tyrosine kinase inhibition in chronic lymphocytic leukemia.
    Maddocks K; Jones JA
    Semin Oncol; 2016 Apr; 43(2):251-9. PubMed ID: 27040703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incorporating targeted agents into future therapy of chronic lymphocytic leukemia.
    Pallasch CP; Hallek M
    Semin Hematol; 2014 Jul; 51(3):235-48. PubMed ID: 25048787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The biological rationale and clinical efficacy of inhibition of signaling kinases in chronic lymphocytic leukemia.
    de Weerdt I; Eldering E; van Oers MH; Kater AP
    Leuk Res; 2013 Jul; 37(7):838-47. PubMed ID: 23597579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma.
    Varma G; Johnson TP; Advani RH
    Clin Adv Hematol Oncol; 2016 Jul; 14(7):543-54. PubMed ID: 27379948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Chronic Lymphocytic Leukemia in the Elderly.
    Barrientos JC
    Cancer Control; 2015 Oct; 22(4 Suppl):17-23. PubMed ID: 26618342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
    Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
    Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Reaserch Advance on Inhibitor Targeting at the B-Cell Receptor Pathway in Chronic Lymphocytic Leukemia --Review].
    Ji TT; Chen QN; Tao SD; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):708-712. PubMed ID: 32319422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib.
    Song Z; Lu P; Furman RR; Leonard JP; Martin P; Tyrell L; Lee FY; Knowles DM; Coleman M; Wang YL
    Clin Cancer Res; 2010 Jan; 16(2):587-99. PubMed ID: 20068106
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting PI3Kδ: emerging therapy for chronic lymphocytic leukemia and beyond.
    Wei M; Wang X; Song Z; Jiao M; Ding J; Meng LH; Zhang A
    Med Res Rev; 2015 Jul; 35(4):720-52. PubMed ID: 25763934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel agents for the treatment of chronic lymphocytic leukemia.
    Abou-Nassar K; Brown JR
    Clin Adv Hematol Oncol; 2010 Dec; 8(12):886-95. PubMed ID: 21326166
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Research Progress of Targeted Therapy for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma --Review].
    Chen D; Wang MY; Tian C
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):643-646. PubMed ID: 38660880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.